PDF SOLUTIONS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PDF SOLUTIONS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $22.37M | Mar 11, 2021 |
| FY2020 | Sep 30, 2020 | $23.11M | Mar 11, 2021 |
| FY2020 | Jun 30, 2020 | $21.41M | Mar 11, 2021 |
| FY2020 | Mar 31, 2020 | $21.16M | Mar 11, 2021 |
| FY2020 | Dec 31, 2019 | $22.56M | Mar 11, 2021 |
| FY2020 | Sep 30, 2019 | $21.91M | Mar 11, 2021 |
| FY2020 | Jun 30, 2019 | $20.57M | Mar 11, 2021 |
| FY2020 | Mar 31, 2019 | $20.54M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $19.73M | Mar 10, 2020 |
| FY2019 | Sep 30, 2018 | $20.21M | Mar 10, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $158.40M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $125.32M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $114.09M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $100.64M | Feb 27, 2025 |
| FY2018 | Dec 31, 2018 | $10.00M | Mar 8, 2019 |
| FY2018 | Sep 30, 2018 | $9.53M | Mar 8, 2019 |
| FY2018 | Jun 30, 2018 | $10.20M | Mar 8, 2019 |
| FY2018 | Mar 31, 2018 | $13.26M | Mar 8, 2019 |
| FY2018 | Dec 31, 2017 | $14.50M | Mar 8, 2019 |
| FY2018 | Sep 30, 2017 | $14.09M | Mar 8, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($640.0K) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $4.06M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $3.11M | Feb 24, 2026 |
| FY2022 | Dec 31, 2022 | $483.0K | Mar 1, 2023 |
| FY2022 | Sep 30, 2022 | $1.39M | Mar 1, 2023 |
| FY2022 | Jun 30, 2022 | ($1.15M) | Mar 1, 2023 |
| FY2022 | Mar 31, 2022 | ($4.15M) | Mar 1, 2023 |
| FY2022 | Dec 31, 2021 | ($7.00M) | Mar 1, 2023 |
| FY2022 | Sep 30, 2021 | ($2.41M) | Mar 1, 2023 |
| FY2022 | Jun 30, 2021 | ($4.48M) | Mar 1, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.85M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $935.0K | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($151.0K) | Feb 24, 2026 |
| FY2018 | Dec 31, 2018 | ($9.95M) | Mar 8, 2019 |
| FY2018 | Dec 31, 2017 | $190.0K | Mar 8, 2019 |
| FY2018 | Dec 31, 2016 | $12.97M | Mar 8, 2019 |
| FY2017 | Dec 31, 2015 | $19.24M | Mar 16, 2018 |
| FY2016 | Dec 31, 2014 | $27.84M | Mar 9, 2017 |
| FY2015 | Dec 31, 2013 | $31.37M | Mar 1, 2016 |
| FY2014 | Dec 31, 2012 | $19.13M | Mar 3, 2015 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $64.23M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $53.57M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $50.74M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $56.13M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $43.78M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $34.65M | Mar 1, 2023 |
| FY2020 | Dec 31, 2019 | $32.75M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $28.00M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $30.08M | Mar 8, 2019 |
| FY2018 | Dec 31, 2016 | $27.56M | Mar 8, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $84.74M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $69.92M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $62.22M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $45.34M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $37.65M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $32.68M | Mar 1, 2023 |
| FY2020 | Dec 31, 2019 | $26.30M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $23.93M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $23.68M | Mar 8, 2019 |
| FY2018 | Dec 31, 2016 | $22.06M | Mar 8, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.05M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $9.70M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $14.60M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $32.30M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $4.24M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $21.78M | Mar 1, 2023 |
| FY2020 | Dec 31, 2019 | $24.59M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $13.34M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $10.55M | Mar 8, 2019 |
| FY2018 | Dec 31, 2016 | $2.00M | Mar 8, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.63M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $17.16M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $11.24M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $8.41M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $3.67M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $6.01M | Mar 1, 2023 |
| FY2020 | Dec 31, 2019 | $10.55M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $13.12M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $10.26M | Mar 8, 2019 |
| FY2018 | Dec 31, 2016 | $11.28M | Mar 8, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $418.70M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $315.29M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $290.14M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $278.67M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $273.77M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $287.58M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $239.54M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $225.91M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $224.18M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $222.33M | Mar 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $147.68M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $69.25M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $61.19M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $68.66M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $54.18M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $53.07M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $43.39M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $26.11M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $25.81M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $23.53M | Mar 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $271.02M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $246.04M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $228.95M | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $210.01M | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | $219.59M | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $234.51M | Feb 27, 2024 |
| FY2022 | Dec 31, 2019 | $196.16M | Mar 1, 2023 |
| FY2020 | Dec 31, 2018 | $199.80M | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | $198.37M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $198.80M | Mar 8, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $95.01M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $14.95M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $15.03M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $14.12M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $14.12M | Feb 27, 2024 |
| FY2023 | Dec 31, 2020 | $15.77M | Feb 27, 2024 |
| FY2022 | Dec 31, 2019 | $2.29M | Mar 1, 2023 |
| FY2019 | Apr 29, 2019 | $370.0K | Mar 10, 2020 |
| FY2020 | Dec 31, 2018 | $2.29M | Mar 11, 2021 |
| FY2018 | Dec 31, 2017 | $1.92M | Mar 8, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($94.63M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($93.99M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($98.05M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($101.15M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($97.72M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($76.23M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($35.87M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($30.45M) | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | ($27.09M) | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | ($25.75M) | Mar 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.22M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $90.59M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $98.98M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $119.62M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $27.68M | Mar 1, 2023 |
| FY2022 | Dec 31, 2020 | $30.32M | Mar 1, 2023 |
| FY2020 | Dec 31, 2019 | $97.61M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $96.09M | Mar 10, 2020 |
| FY2019 | Dec 31, 2017 | $101.27M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $116.79M | Mar 8, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.00M | Feb 24, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 24, 2026 |
| FY2022 | Dec 31, 2022 | 0 | Mar 1, 2023 |
| FY2022 | Sep 30, 2022 | 0 | Mar 1, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Mar 1, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Mar 1, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Mar 1, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Mar 1, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Mar 1, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 24, 2026 |
| FY2022 | Dec 31, 2022 | 0 | Mar 1, 2023 |
| FY2022 | Sep 30, 2022 | 0 | Mar 1, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Mar 1, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Mar 1, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Mar 1, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Mar 1, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Mar 1, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 39.54M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 38.80M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 38.29M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 37.43M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 37.41M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 36.85M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 32.50M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | 32.38M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | 32.11M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | 31.86M | Mar 16, 2018 |